Recent developments in biomedicine techniques allow the integration of omics and non-omics data and have revealed molecular heterogeneity in allergic disorders and glioma, with specific molecular subtypes related to disease severity, prognosis, and treatment options.9-12 There are a range of phenotypes and endotypes for allergic diseases, such as allergic and non-allergic asthma or rhinitis. Advancing neuropathological, cellular, and molecular approaches, including DNA aberrations and methylation profiles, have revealed heterogeneity in glioma classification.10 Adopting up-to-date molecular and genetic sub-classification approaches is relevant for research in AllergoOncology to further improve understanding of immune-glioma interactions.
In this Position Paper, members of the European Academy of Allergy & Clinical Immunology (EACCI) and the European Association of Neuro-Oncology (EANO) jointly provide an overview of strategies for defining allergic diseases and adult-type diffuse gliomas. The paper summarizes biomarkers for diagnosing and managing both conditions. It provides a narrative review of the epidemiological and pre-clinical evidence on associations between allergy and glioma. Additionally, the paper outlines how emerging allergy biomarkers can be utilized in next-generation AllergoOncology studies to enhance understanding of the aetiology and clinical management of glioma patients.